These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12216268)

  • 21. [Pharmacological treatment of pathological increases in muscle tonus].
    Reisner H
    Wien Med Wochenschr; 1978 Feb; 128(3):57-62. PubMed ID: 625998
    [No Abstract]   [Full Text] [Related]  

  • 22. Multiple sclerosis. Treatment.
    Champion de Crespigny JV
    Aust Fam Physician; 1979 Feb; 8(2):163-8. PubMed ID: 426733
    [No Abstract]   [Full Text] [Related]  

  • 23. Spasticity, ataxia and fatigue in multiple sclerosis.
    Kesselring J; Thompson AJ
    Baillieres Clin Neurol; 1997 Oct; 6(3):429-45. PubMed ID: 10101582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spasticity management in multiple sclerosis.
    Hughes C; Howard IM
    Phys Med Rehabil Clin N Am; 2013 Nov; 24(4):593-604. PubMed ID: 24314678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Spasticity and everyday life in multiple sclerosis].
    Donzé C; De Sèze J
    Rev Neurol (Paris); 2012 Apr; 168 Suppl 3():S51-6. PubMed ID: 22721365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple sclerosis symptom management.
    Boissy AR; Cohen JA
    Expert Rev Neurother; 2007 Sep; 7(9):1213-22. PubMed ID: 17868019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New insights in the pathophysiology and treatment of multiple sclerosis spasticity and related symptoms. Foreword.
    Montalbán X
    Expert Rev Neurother; 2011 Apr; 11(4 Suppl):1. PubMed ID: 21449852
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of acute unloaded leg cycling on spasticity in individuals with multiple sclerosis using anti-spastic medications.
    Motl RW; Snook EM; Hinkle ML
    Int J Neurosci; 2007 Jul; 117(7):895-901. PubMed ID: 17613103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation.
    Giacoppo S; Bramanti P; Mazzon E
    Mult Scler Relat Disord; 2017 Oct; 17():22-31. PubMed ID: 29055461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New insights into multiple sclerosis and advances in multiple sclerosis spasticity management.
    Gold R
    Expert Rev Neurother; 2013 Dec; 13(12 Suppl):1-2. PubMed ID: 24289835
    [No Abstract]   [Full Text] [Related]  

  • 31. Who benefits most from THC:CBD spray? Learning from clinical experience.
    Koehler J
    Eur Neurol; 2014; 71 Suppl 1():10-5. PubMed ID: 24457847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.
    Bramanti P; Sessa E; Rifici C; D'Aleo G; Floridia D; Di Bella P; Lublin F
    Neurology; 1998 Dec; 51(6):1720-3. PubMed ID: 9855531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis.
    Meuth SG; Vila C; Dechant KL
    Expert Rev Neurother; 2015; 15(8):909-18. PubMed ID: 26166264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Non-medicinal treatments of spasticity in multiple sclerosis].
    Mailhan L; Papeix C
    Rev Neurol (Paris); 2012 Apr; 168 Suppl 3():S57-61. PubMed ID: 22721366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The high cost of spasticity in multiple sclerosis to individuals and society.
    Stevenson VL; Gras A; Bárdos JI; Broughton J
    Mult Scler; 2015 Oct; 21(12):1583-92. PubMed ID: 25623252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Common Etiologies of Upper Extremity Spasticity.
    Angulo-Parker FJ; Adkinson JM
    Hand Clin; 2018 Nov; 34(4):437-443. PubMed ID: 30286958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cannabis based drug is licensed for spasticity in patients with MS.
    Kmietowicz Z
    BMJ; 2010 Jun; 340():c3363. PubMed ID: 20570870
    [No Abstract]   [Full Text] [Related]  

  • 38. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
    Haupts M; Vila C; Jonas A; Witte K; Álvarez-Ossorio L
    Eur Neurol; 2016; 75(5-6):236-43. PubMed ID: 27160412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of repetitive transcranial magnetic stimulation (rTMS) for the treatment of spasticity.
    Mori F; Koch G; Foti C; Bernardi G; Centonze D
    Prog Brain Res; 2009; 175():429-39. PubMed ID: 19660671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Consensus document on spasticity in patients with multiple sclerosis. Grupo de Enfermedades Desmielinizantes de la Sociedad Española de Neurología].
    Oreja-Guevara C; Montalban X; de Andrés C; Casanova-Estruch B; Muñoz-García D; García I; Fernández Ó;
    Rev Neurol; 2013 Oct; 57(8):359-73. PubMed ID: 24081891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.